Halozyme Therapeutics (HALO) Cash from Operations Growth (3y) (2013 - 2026)
Halozyme Therapeutics (HALO) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Halozyme Therapeutics | 9.65 Bn | 9.33 Bn | 297.47 Mn | 27.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.46% |
| Dec 31, 2025 | 38.49% |
| Sep 30, 2025 | 36.88% |
| Jun 30, 2025 | 35.34% |
| Mar 31, 2025 | 47.77% |
| Dec 31, 2024 | 29.32% |
| Sep 30, 2024 | -1.77% |
| Jun 30, 2024 | 14.79% |
| Mar 31, 2024 | 30.46% |
| Dec 31, 2023 | 26.20% |
| Sep 30, 2023 | 179.20% |
| Jun 30, 2023 | 172.76% |
| Mar 31, 2023 | 171.23% |
| Dec 31, 2022 | 72.09% |
| Sep 30, 2022 | 63.28% |
| Jun 30, 2022 | 53.59% |
| Mar 31, 2022 | 133.95% |
| Dec 31, 2021 | 99.06% |
| Sep 30, 2021 | 103.54% |
| Jun 30, 2021 | 58.16% |